SWOG clinical trial number
S1900BDSS
S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)
Open
Abbreviated Title
S1900BDSS Version Control Protocol
Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Activated
01/28/2019
Research committees
Lung Cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open